NASDAQ:VRTX

Vertex Pharmaceuticals (VRTX) Price Target & Analyst Ratings

$347.74

-4.76 (-1.35%)

(As of 09/29/2023 ET)

Compare

Today's Range: $347.26
▼
$354.18
50-Day Range: $340.48
▼
$358.40
52-Week Range: $282.21
▼
$367.00

Volume: 896,813 shs
Average Volume: 857,042 shs
Market Capitalization: $89.75 billion

P/E Ratio: 26.85
Dividend Yield: N/A
Price Target: $367.23

Vertex Pharmaceuticals Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 18 Analyst Ratings

Consensus Analyst Price Target

$367.23
5.60% Upside

High Prediction	$456.00
Average Prediction	$367.23
Low Prediction	$296.00

Type	Current 10/1/22 to 10/1/23	1 Month Ago 9/1/22 to 9/1/23	3 Months Ago 7/3/22 to 7/3/23	1 Year Ago 10/1/21 to 10/1/22
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	12 Buy rating(s)	11 Buy rating(s)	9 Buy rating(s)	11 Buy rating(s)
Hold	6 Hold rating(s)	6 Hold rating(s)	6 Hold rating(s)	6 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$367.23	$366.92	$357.54	$291.65
Predicted Upside	5.60% Upside	9.27% Upside	12.01% Upside	12.48% Upside

Get Vertex Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for VRTX and its competitors with MarketBeat's FREE daily newsletter.

VRTX Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

VRTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Vertex Pharmaceuticals Stock vs. The Competition

Type	Vertex Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.67	2.66	2.49
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	5.60% Upside	869.81% Upside	698.21% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Historical Target Prices and Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/29/2023	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Sector Perform ➝ Sector Perform	$343.00 ➝ $348.00	-1.28%
9/7/2023	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$370.00	+6.94%
8/7/2023	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$312.00 ➝ $315.00	-7.48%
8/2/2023	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$380.00	+6.03%
8/2/2023	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$410.00	+14.40%
8/2/2023	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$385.00 ➝ $389.00	+8.54%
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
8/2/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$340.00 ➝ $352.00	-1.79%
8/2/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$410.00 ➝ $425.00	+21.54%
8/2/2023	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$380.00 ➝ $390.00	+12.15%
8/2/2023	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$384.00 ➝ $399.00	+14.74%
7/21/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$350.00 ➝ $400.00	+10.55%
6/26/2023	888 Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Reiterates
6/26/2023	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$375.00 ➝ $379.00	+7.05%
5/30/2023	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Minter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$382.00	+15.76%
5/25/2023	Westpark Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold
5/3/2023	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$325.00 ➝ $400.00	+15.60%
5/2/2023	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$341.00 ➝ $456.00	+29.99%
5/2/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$300.00 ➝ $340.00	-1.45%
5/2/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$339.00 ➝ $385.00	+11.59%
5/2/2023	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$280.00 ➝ $325.00	-5.80%
3/29/2023	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$340.00 ➝ $350.00	+11.73%
2/8/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral	$296.00	-1.62%
2/8/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$374.00 ➝ $365.00	+18.30%
2/8/2023	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$374.00 ➝ $365.00	+18.30%
12/19/2022	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$340.00	+11.55%
10/28/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$315.00 ➝ $330.00	+10.34%
10/24/2022	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight	$319.00 ➝ $327.00	+10.53%

(Data available from 10/1/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

VRTX Price Target - Frequently Asked Questions

What is Vertex Pharmaceuticals's consensus rating and price target?: According to the issued ratings of 18 analysts in the last year, the consensus rating for Vertex Pharmaceuticals stock is Moderate Buy based on the current 6 hold ratings and 12 buy ratings for VRTX. The average twelve-month price prediction for Vertex Pharmaceuticals is $367.23 with a high price target of $456.00 and a low price target of $296.00. Learn more on VRTX's analyst rating history.
Do Wall Street analysts like Vertex Pharmaceuticals more than its competitors?: Analysts like Vertex Pharmaceuticals more than other Medical companies. The consensus rating score for Vertex Pharmaceuticals is 2.67 while the average consensus rating score for medical companies is 2.66. Learn more on how VRTX compares to other companies.
Does Vertex Pharmaceuticals's stock price have much upside?: According to analysts, Vertex Pharmaceuticals's stock has a predicted upside of 9.30% based on their 12-month price targets.

What analysts cover Vertex Pharmaceuticals?: Vertex Pharmaceuticals has been rated by Bank of America, Barclays, BMO Capital Markets, Canaccord Genuity Group, Cantor Fitzgerald, HC Wainwright, Morgan Stanley, Oppenheimer, Royal Bank of Canada, Sanford C. Bernstein, and Wells Fargo & Company in the past 90 days.

Stock Ratings Reports and Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

This page (NASDAQ:VRTX) was last updated on 10/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial